India Globalization Capital Inc

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, focusing primarily on Alzheimer's disease in the United States and Colombia. Its lead product, IGC-AD1, is in Phase II clinical trials for treating agitation in dementia due to Alzheimer's. Preclinical candidates include TGR-63 and IGC-M3 for Alzheimer's disease, and the company is also developing MINT-AD, an AI-driven assistant for healthcare providers. Formerly known as India Globalization Capital, Inc., it changed its name to IGC Pharma, Inc. in March 2023, was incorporated in 2005, and is headquartered in Potomac, Maryland.